The KAP survey on liver disease, hepatitis B and EPI was conducted in Quang Xuong and Ngoc Lac (Thanh Hoa) in October 2000. The results: there were more than 50% of interviewees giving completely correct answers on liver disease. Monthly visits of EPI staffs increased three times in Ngoc Lac to compare with this of 3 years ago. Radio/TV and loudspeakers are still the main ways to inform EPI activities. Knowledge of mothers on vaccination has been improved. The rate of having birth at CHS has increased in Ngoc Lac (from 6.2% to 34.2%)
Hepatitis, Chronic ; hepatitis B

No abstract available.
Hepatitis B, Chronic* ; Hepatitis, Chronic*

No abstract available.
Hepatitis B, Chronic* ; Hepatitis, Chronic*

No abstract available.
Hepatitis B, Chronic* ; Hepatitis, Chronic*

A study on 56 patients with chronic hepatitis B who were divided into 2 groups: study group and control group. The study group including 31 patients was treated with Thymosin-α1 1.6mg/day, twice a week for 6 months. The control group with 25 patients of same clinical data was treated with common liver-protective drugs. Both groups were monitored and assessed after 24 months. The results showed that the study group with treatment of Thymosin-α1 is better than control one in all aspects of ALT normalization, sero-conversion and decrease of HBV-DNA<5 copies/ml
Hepatitis B, Chronic ; Therapeutics

Study on 60 patients with chronic hepatitis at Infectious diseases department, hospital 103 from February to July 2003. Patients were divided into 2 groups: group 1 included 30 patients who were treated by Atcanninh pack 20g, 3 packs/day; group 2 included 30 patients who were treated by glucose, bile tonic drug, Vitamin B, C. Results: Atcanninh could reduce rapidly some clinical symptoms as fatigue, lose appetite, jaundice, yellow urine. It reduced quickly the blood level of SGOT, SGPT and Bilirubin after 2 to 3 weeks of treatment. Comparing to control group, Atcanninh reduced significantly HBsAg, HBV-DNA concentrations and rate of seroconversion also higher (14.3% compares to 0% with p<0.05) after 3 months
Hepatitis B, Chronic ; Therapeutics

About 5% of the population worldwide (approximately 400 million people) is infected hepatitis B virus (HBV). Over time, 15-40% of chronic HBV-infected people developed cirrhosis. Mortality due to liver failure or other complications of cirrhosis or liver cancer is a global problem. There are about 0.5 million people newly with diagnosed liver cancer annually worldwide, HBV is one of leading causes of liver cancer, especially in the Western Pacific (in which includes Viet Nam). Limitation of HBV infection and treatment of chronic hepatitis B are important for the prevention of cirrhosis and liver cancer in areas with high HBV-infected rate. Comparison with drugs for chronic hepatitis B treatment, telbividine is a novel medicine that was approved recently for clinical trials. The article gave some results of preclinical, phase I/II, IIb, III trials and of study comparing tebivudine with adefovir dipivoxil. The mechanisms of action, pharmacokinetics, side-effects and anti-drug mutations of tebivudine were also mentioned. The author concluded that tebivudine had relatively high possibility of inhibiting replications, had effects for treatment of both positive and negative HBeAg chronic hepatitis B groups.
Chronic hepatitis B ; tebivudine

Hepatitis B, Chronic ; Humans

Hepatitis B, Chronic ; Humans

Hepatitis B, Chronic ; Phytotherapy